Federal regulators have identified a common thread running through a string of injuries at wellness clinics: at least 30 patients had adverse reactions after intravenous glutathione, and the pharmacies involved all bought the same ingredient from the same supplier lot.
The Food and Drug Administration named the source in an alert issued August 27. Different compounding pharmacies all obtained their glutathione from Medisca Inc., whose U.S. headquarters is in Plattsburgh, New York, under lot number 229536. That material was labeled as dietary supplement grade, which the agency states is not an appropriate ingredient for making injectable drugs.
The reported reactions were not mild. The agency lists fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms, noting that some patients are hospitalized. That is a meaningful escalation from what was publicly known earlier this month, when two Texas pharmacies had each pulled product without any named upstream cause.
For anyone who has had an IV drip at a med spa or wellness clinic this summer, the practical consequence is specific. The recalls issued so far cover particular lots from particular pharmacies. The ingredient problem the agency has now described is broader than those lots because a single supplier batch can be distributed to many compounders, each of whom makes their own product under their own labels.
One Supplier Lot Links Two Separate Recalls
The agency says Medisca notified it on August 20 that the company had sent its United States customers a warning not to use its dietary-supplement-grade glutathione to compound injectable drugs. Regulators are urging compounders who received that material to contact their own customers and tell them to discontinue use of the resulting product.
Two Texas pharmacies have already conducted recalls tied to elevated endotoxin levels in glutathione injections, as the agency's compounding alert confirms. MedicalDaily reported on the first, an Austin pharmacy that recalled three lots to the patient level after its own testing found elevated endotoxin, and on a Houston pharmacy recall whose product reached patients in 14 states.
At the time, the shared failure pointed to something upstream that had not been named. It now has been. That does not mean every compounded glutathione product is affected, and the agency has not published a list of every pharmacy that received the lot.
This is also not the first time the agency has raised the issue. It flagged the same concern years earlier, in a 2019 communication about using dietary ingredient glutathione to compound sterile injectables, and says it remains concerned about continued risks to patients.
Endotoxin deserves a plain explanation because it behaves unlike an infection. It is a component of the outer membrane of certain bacteria and can remain in a product even after sterilization kills the organisms. A vial can pass a sterility test and still carry a hazardous endotoxin load. When injected directly into a vein, it can trigger a rapid and severe immune response.
Med Spa Customers Sit Outside the Recall Chain
The households most exposed here are the ones least likely to hear about a recall. Injectable glutathione is marketed for skin brightening, cellular detoxification, immune support, and general wellness, and is typically administered at med spas, wellness clinics, and IV drip bars rather than in hospitals or doctors' offices, where safety notices are circulated through established channels.
A patient in that setting usually never sees a vial, a lot number, or a pharmacy name. Recall notices reach prescribers and clinics; they do not reach the person who booked an infusion online.
There is also a regulatory point worth stating plainly. The agency has not approved any injectable glutathione product. Compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or quality. None of the uses being marketed rests on approved labeling.
Anyone considering an infusion can ask three questions before booking: which compounding pharmacy supplies the product, whether that pharmacy has had a recall this year, and what the lot number is. A clinic that cannot answer the first question cannot reach you if a recall arrives.
What the Reported Reactions Looked Like
The symptoms the agency describes are consistent with exposure to excessive endotoxin levels: fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms. The agency adds that endotoxin exposure can also cause muscle pain, headache, nausea, vomiting, low blood pressure, and death, while noting that not all of those outcomes have been reported in connection with these particular events.
Anyone who feels unwell after a recent infusion should contact the clinician who administered it and mention the product and timing. Difficulty breathing, throat tightness, facial swelling, chest pain, fainting, confusion, or a rapidly spreading rash warrant emergency care rather than a phone call. This article provides general information and is not a diagnosis; nobody should stop a prescribed medication because of it.
An Investigation That Is Still Open
Regulators say they continue to receive adverse event reports consistent with endotoxin exposure and are actively investigating, with updates promised as more becomes available.
Several things remain unknown. The agency has not said how many compounding pharmacies received the affected material, how many patients were exposed, how many required hospitalization, or whether additional recalls will follow. It has not stated whether the 30 reported cases are confined to the two pharmacies that have already recalled product. No enforcement action against any company has been announced, and the identification of a supplier lot is not a finding of legal fault.
The agency's guidance to industry is direct: compounders are responsible for ensuring every component of an injectable drug is appropriate for its intended use, should know their ingredient suppliers, and should not rely on testing alone, because quality has to be built into every step of the process rather than caught at the end. Health care professionals are advised to check with their compounders about the source of the glutathione.
Consumers and clinicians can report problems through the MedWatch program, which is how the reports behind this alert accumulated. MedicalDaily will report additional recalls, an updated case count, or any enforcement action as it is published.
Key Questions Answered
What did federal regulators announce? An alert stating that at least 30 patients had adverse reactions after IV glutathione, and that the pharmacies involved all sourced the ingredient from Medisca lot 229536, labeled as dietary supplement grade.
Why does the grade of the ingredient matter? Material labeled for dietary supplement use may contain impurities and contaminants, including endotoxins, that can be harmful when injected directly into the bloodstream rather than swallowed.
What is endotoxin? A component of the outer membrane of certain bacteria. It can persist after sterilization kills the bacteria, so a product can pass a sterility test and still carry a dangerous load.
Which symptoms were reported? Fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms. The agency says endotoxin exposure can also cause muscle pain, headache, nausea, vomiting, and low blood pressure.
When is emergency care needed? Difficulty breathing, throat tightness, facial swelling, chest pain, fainting, confusion, or a rapidly spreading rash require urgent evaluation.
Is injectable glutathione FDA-approved? No. It is compounded and marketed for uses not approved in the labeling. Compounded drugs do not undergo premarket review for safety, effectiveness, or quality.
What should someone ask before an infusion? Which compounding pharmacy supplies the product, whether that pharmacy has had a recall this year, and the lot number.
